NCT06625047CompletedPhase 4
Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy
Neuro-Oncology Anywhere 242: Pilot Study Evaluating Telehealth and In-Person Assessments in Patients With Glioma Receiving Oral Chemotherapy
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
This phase IV trial compares patient satisfaction with telehealth versus in-person neuro-oncology assessments among glioma patients receiving oral chemotherapy. Gliomas are the most common primary central nervous system cancer and are associated with a high symptom burden, such as drowsiness, fatigue, memory difficulty, and difficulty communicating. Care at a high volume center is associated with an overall survival benefit, however, many patients may have physical or financial difficulties preventing access to these centers. Telehealth visits use computers, cameras, videoconferencing, the internet, satellite, and wireless communications to deliver healthcare, while in-person visits require the interaction to take place in the physical presence of someone else. Telehealth neuro-oncology assessments may be preferable compared to in-person assessments in glioma patients receiving oral chemotherapy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 1 Oct 2024
- Start date
- 7 Oct 2024
- Primary completion date
- 12 Nov 2025
- Lead sponsor
- Mayo Clinic
- Diseases
- Glioblastoma
- NCT number
- NCT06625047
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 30
- From 7 Oct 2024 to the primary completion date, 12 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Unable to swallow tablets or at risk for impaired absorption of oral medication
Other illness
- Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings
- Known hypersensitivity or allergy to temozolomide
Other
- Pregnant or nursing, imprisoned, or lacking capacity for understanding
Who the study is looking for
- Age ≥ 18 years
- Diagnosis of glioma requiring adjuvant chemotherapy. Patients with glioblastoma (GBM); astrocytoma, IDH-mutant; oligodendroglioma IDH-mutant, 1p/19q codeleted are eligible
- Patients eligible to receive temozolomide as standard of care adjuvant therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, AND Karnofsky performance status (KPS) of ≥ 60
- Expected survival ≥ 6 months in the opinion of treatment team
- Willing and able to adhere with the protocol for the duration of the study including undergoing treatment, and attending scheduled visits, and examinations
- Participants who do not have devices that will permit telehealth visits will be provided such tablet devices to facilitate appointments for the duration of the study
- Participants who do not have financial resources to travel for in-person visits will be provided assistance for cost of travel
- Ability to complete patient experience surveys by the participant with or without assistance from their caregiver
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
Related publications
- Protocol for neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapy.Contemp Clin Trials Commun · 2026 · PMID 41567708
This page is information, not medical advice. Discuss any trial with your doctor.